Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
RESEARCH TOOLSreports
Holding TECX?
Track your performance easily
TECX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.12 - $19.61
Previous Close$18.47
Volume20.09K
Average Volume (3M)28.29K
Market Cap
$272.15M
Enterprise Value$90.47M
Total Cash (Recent Filing)$185.12M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 14, 2024EPS Estimate
-$1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.34
Shares Outstanding14,734,479
10 Day Avg. Volume29,425
30 Day Avg. Volume28,288
Standard Deviation0.21
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.64
Price to Sales (P/S)4908.76
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.92K
Enterprise Value/Gross Profit-44.32
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$60.00Price Target Upside224.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Tectonic Therapeutic News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FDA cleared the IND for Ph2 for TX45, and in August it activated the first clinical trial site for the global 24-week Phase 2 clinical trial (named APEX).
Financial PerformanceTECX’s cash & cash equivalents were $185M as of June 30, 2024, and when adjusted for transaction-related expenses which were paid in July were in line with our estimate of $171M.
Scientific AdvancementsTX45 is a long-acting relaxin with a differentiated drug profile for the treatment of PH-HFpEF, which currently has no approved Rx therapies.
Bears Say
Clinical DevelopmentClinical development failures of all drugs studied in Group 2 PH.
CompetitionPotential competition from AZN, MRK, and LLY.
Pharmaceutical ResearchClinical development failures of all drugs studied in Group 2 PH.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $12.12 and its highest was $19.61 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Currently, no data Available
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Aug 14, 2024 which is 37 days ago.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on May 09, 2024. The company reported -$0.152 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.208.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -$1.3.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 14,734,479 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$0.152 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 5.23%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Among the largest hedge funds holding Tectonic Therapeutic’s share is Farallon Capital Management, L.L.C.. It holds Tectonic Therapeutic’s shares valued at 7M.
---
Tectonic Therapeutic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.00 (224.85% Upside)
$60.00 (224.85% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 431.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.27%
12-Months-Change
Fundamentals
Return on Equity
-34.56%
Trailing 12-Months
Asset Growth
44.89%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
---
TECX Stock 12 Month Forecast
Average Price Target
$60.00
▲(224.85% Upside)
Technical Analysis
Best Analysts Covering TECX
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+9.05%
reiterated a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.05% per trade.
---